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A B S T R A C T
The formulation and device collectively constitute an inhalation drug product. Develop-
ment of inhaled drugs must consider the compatibility between formulation and device in
order to achieve the intended pharmaceutical performance and usability of the product to
improve patient compliance with treatment instruction. From the points of formulation,
device and patient use, this article summarizes the inhalation drugs, including pressur-
ized metered dose inhaler (pMDI), dry powder inhaler (DPI), and nebulizer that are currently
available in the US and UK markets. It also discusses the practical considerations for the
development of inhalers and provides an update on the corresponding regulations of the
FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency).
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Respiratory drug delivery has strong interest in the pharma-
ceutical field from both industries and academics, due to the
fact that inhalation therapy not only has been widely ac-
cepted for localized treatment for pulmonary diseases such as
asthma and chronic obstructive pulmonary disease (COPD), but
also as an alternative route for systemic drug administration
for diseases such as diabetes [1]. For local activities, the orally
inhaled drugs are delivered directly to the site of action in the
lung, providing fast onset of action (within 5 minutes) [2]. A
sustained activity can also be achieved by utilizing long-acting
drugs (e.g., salmeterol and tiotropium) and/or by modifying for-
mulation technology to bettermeet the clinical needs and patient
compliance [3,4]. In the case of systemic drug delivery via in-
halation, the lung provides the advantage of large alveolar
epithelial absorption area with low enzymatic activity, which
makes it a suitable route for biological products such as insulin.
Drugs absorbed through the lung can also avoid first-pass me-
tabolism and have thus shown an improved bioavailability.
Inhalation drug products are commonly classified into three
categories: pressurizedmetered dose inhaler (pMDI),dry powder
inhaler (DPI) and nebulizer.All these inhalation drug products
are a combination of formulation and device, with patient use
as the target consideration (Fig. 1).The formulation is designed
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to provide intended efficacy for patients, and to achieve this
goal, it needs to be compatible andworks togetherwith a device.
An inhalation product should be able to provide consistent dose
content, along with suitable aerodynamic particle size distri-
bution, to ensure that the drugs can be efficiently delivered to
the target sites in the lung. A well-designed inhaler must also
consider its usability for patients’ use in terms of features such
as robustness, ease of use, portability, and suitability for all ages
in order to achieve good patient compliance with the tech-
nique instructions.
The development of an inhalation product must take into
account of the following factors: (a) type of drugs being deliv-
ered to the lung, such as local or systemic action, chemical or
biological drug, and dose and frequency for patient use;
(b) physico-chemical properties of the drug substance, such as
solubility profile, particle size,morphology and density, as these
determine the formulation development; (c) type of formula-
tion (e.g., dry powder, propellant driven liquid, or aqueous
inhalation formulation) being selected to deliver the drug;
(d) device design for compatibility with the formulation to be
suitable for the targeted patient population.
Each type of inhaler has its specific formulation, device and
clinical advantages. The inhalation products currently avail-
able in the US and UK markets are summarized in Tables 1–3
for pMDIs, DPIs and nebulizers, respectively. Based on these
product’s formulation and device information, this article dis-
cusses the practical strategies and clinical considerations for
the development of each type of inhalers and provides an
update for the regulatory guidelines issued by the FDA and EMA
for these inhalers, specifically for generic inhalation prod-
ucts. Any new technology and new inhalation drug that are
still under the investigation phases will be briefly mentioned.
2. pMDIs
2.1. Formulation
pMDIs are either suspension or solution based formulation of
drug in propellants. The traditional chlorofluorocarbon (CFC)
propellants, which have previously been used in pMDIs for
decades, were banned by the Montreal Protocol (1989) due to
their ozone depletion effect. The hydrofluoroalkanes (HFA-
134a and HFA 227) were selected as alternative propellants.This
propellant transition for pMDIs is almost complete in western
countries [5]. All researches for pMDI development are re-
ferred to the landmark publication by Vervaet and Byron to
further understand the drug–surfactant–propellant interac-
tions in the HFA formulations. That article systemically
presented an overview of the present state-of-the-art with
respect to the physico-chemical characteristics of HFA and HFA–
ethanol blends, drug substance properties that need to be
considered for formulation development, and surfactant be-
haviors in the pMDI formulations [6].The important properties
of the drug substance such as solubility profile, particle size,
morphology and density, need to be characterized first, as these
parameters will influence the formulation decision (solution
or suspension) and drug micronization method selection [7].
As for the surfactants in suspension formulations, such as oleic
acid in Proventil and polyethylene glycol (PEG) 1000 in
Symbicort, they serve to lubricate the valves to improve the
drug delivery efficiency and dose uniformity. However, the sur-
factants previously soluble in the CFC formulations, especially
the surfactants with low hydrophilic-lipophilic balance (HLB)
values, show decreased solubility in the HFA propellants. More
hydrophilic surfactants with higher HLB values, such as PEG,
tend to dissolve more in HFAs [6]. Co-solvents such as anhy-
drous ethanol may also needed to help improve the
solubilization of the surfactants in the HFA formulations, but
the ethanol content in pMDI suspension formulations should
be minimized to avoid the dissolution of drug.This is because
the partly soluble micronized drug may lead to crystal growth
(Ostwald ripening: a phenomenon in suspension that de-
scribes the change of an inhomogeneous structure over time,
i.e., small crystals or particles dissolve, and redeposit onto larger
crystals or particles), resulting to reduced drug delivery con-
sistency and increased particle size distribution [6]. Ethanol can
also be used to increase the solubility of drug to form a solu-
tion formulation, such as Qvar (Beclomethasone dipropionate
solution formulation). Such a solution formulation generates
significantly smaller particle size compared to the typical sus-
pension formulation, leading to reduced oropharyngeal
deposition and improved lung deposition [8]. Having said that,
the ethanol content in solution formulations must be bal-
anced, as higher ethanol concentration can lead to decreased
fine particle fraction, mainly due to the increase in initial at-
omized droplet size that subsequently affects solvent
evaporation [9,10]. The chemical stability of drug could also be
an issue for solution formulations [11,12]. In Atrovent, a solu-
tion formulation of ipratropium bromide, water and citric acid
are added to improve the drug chemical stability. Citric acid
acts as an organic acid, provides stability against degradation
or decomposition of the medicament resulting largely from in-
teraction of the medicament with the cosolvent and/or water
present in the solution formulation [13]. The physical stabil-
ity such as drug particle agglomeration and adsorption is a
challenge to formulate a suspension formulation. Suspend-
ing agents, such as povidone K25 in Symbicort, are used to
improve the drug particle suspension [14]. Suspending agents
can increase suspension viscosity and/or provide steric hin-
drance to aid the stabilization of microparticles in the pMDI
Fig. 1 – Overall considerations for development of
inhalation drug products.
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formulations [15,16]. Moisture ingress could also damage the
stability of suspension formulations [17]. In summary, to for-
mulate a stable pMDI formulation, the physico-chemical
property, such as solubility, particle size, morphology and
density of drug substance, type of surfactants and/or suspend-
ing agents for stabilizing the formulation, use of ethanol as co-
solvent for improving the solubility of surfactants and drug,
should be systemically studied [6,18].
2.2. Container closure system
The physical and chemical compatibility between pMDI for-
mulation and container closure system components (including
metering valve, canister and actuator) is critical for a success-
ful development of pMDI. The target dose to be delivered is
determined by the combination of drug concentration and the
chamber volume of the metering valve (typically 25–100 μL).
The valve materials may influence the drug’s physical uptake,
drug chemical degradation, moisture ingress and leak rate
[17,19]. The extractable and leachable profiles of the valve ma-
terials must also be thoroughly investigated, and the leachables
from these materials into the pMDI formulations should be
closely monitored during product development [7,20].The pMDI
containers are normally aluminum canisters, which could cause
drug loss through adsorption onto the canister and catalyze
the chemical degradation [12,21,22]. Inner wall coated con-
tainers may be used to replace the aluminum canisters. The
common coatings are epoxy-phenolic polymer (Epoxy),
polytetrafluoroethylene (PTFE), perfluorinated ethylene pro-
pylene copolymer (FEP), perfluoroalkoxyalkane polymer (PFA),
and polyethersulfone (PES) [22,23]. Appropriate size contain-
ers should also be selected based on the actual formulation
Table 1 – The pressurized metered dose inhalers in the US & UK markets.
Indications APIs Products Manufacturer Formulation Device
Asthma
and
COPD
Albuterol sulfate Proair Teva Drug, HFA-134a, Ethanol
(Suspension)
Valve, Canister, Acuator
Proventil Merck Drug, HFA-134a, Ethanol,
Oleic acid (Suspension)
Valve, Canister, Acuator
Ventolin GlaxoSmithKline Drug, HFA-134a
(Suspension)
Valve, Canister, Acuator
with dose counter
Salbutamol xinafoate AirSalb Sandoz Drug, HFA-134a, Ethanol,
Oleic acid (Suspension)
Valve, Canister, Acuator
Levalbuterol tartrate Xopenex Sunovion Drug, HFA-134a, Ethanol,
Oleic acid (Suspension)
Valve, Canister, Acuator
Formoterol fumarate Atimos
Modulite
Chiesi Drug, HFA-134a, Ethanol,
Hydrochloric acid (Solution)
Valve, Canister, Acuator
Ipratropium bromide Atrovent Boehringer
Ingelheim
Drug, HFA-134a,Water,
Ethanol, Citric acid
(Solution)
Valve, Canister, Acuator
with dose counter
Sodium cromoglycate Intal Sanofi Aventis Drug, HFA-227, Polyvidone
K30, Polyethylene glycol 600
(Suspension)
Valve, Canister, Acuator
Beclomethasone
dipropionate
Clenil
Modulite
Chiesi Drug, HFA-134a, Ethanol,
Glycerol (Solution)
Valve, Canister, Acuator
Qvar Teva Drug,HFA-134a, Ethanol
(Solution)
Valve, Canister, Acuator
Qvar
Autohaler
3M Drug,HFA-134a, Ethanol
(Solution)
Valve, Canister, Breath-
activated Acuator
Ciclesonide Alvesco Takeda Drug,HFA-134a, Ethanol
(Solution)
Valve, Canister, Acuator
with dose counter
Flunisolide Aerospan Meda Drug,HFA-134a, Ethanol
(Solution)
Valve, Canister, Acuator
with spacer
Fluticasone propionate Flovent GlaxoSmithKline Drug,HFA-134a
(Suspension)
Valve, Canister, Acuator
with dose counter
Beclomethasone
dipropionate + Formoterol
fumarate
Fostair Chiesi Drug, HFA-134a, Ethanol,
Hydrochloric acid (Solution)
Valve, Canister, Acuator
Budesonide + Formoterol
fumarate
Symbicort AstraZeneca Drug, HFA 227, Povidone
K25, Polyethylene glycol
1000 (Suspension)
Valve, Canister, Acuator
with dose counter
Fluticasone
propionate + Formoterol
fumarate
Flutiform Napp Drug, HFA-227, Sodium
cromoglicate, Ethanol
(Suspension)
Valve, Canister, Acuator
with dose counter
Fluticasone
propionate + Salmeterol
xinafoate
Advair GlaxoSmithKline Drug,HFA-134a
(Suspension)
Valve, Canister, Acuator
with dose counter
Mometasone
furoate + Formoterol
fumarate
Dulera Merck Drug, HFA-227, Ethanol,
Oleic acid (Suspension)
Valve, Canister, Acuator
with dose counter
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Table 2 – The dry powder inhalers in the US & UK markets.
Indications APIs Products Manufacturer Formulation Device type
Asthma
and
COPD
Albuterol sulfate ProAir Respiclick Teva Drug, Lactose monohyrdrate Passive, Reservoir,
Multiple dose
Salbutamol sulfate Pulvinal
Salbutamol
Chiesi Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Easyhaler
Salbutamol Sulfate
Orion Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Terbutaline sulfate Bricanyl
Turbohaler
AstraZeneca Drug Passive, Reservoir,
Multiple dose
Salmeterol xinafoate Serevent Diskus GlaxoSmithKline Drug, Lactose monohydrate Passive, Blister strip,
Multiple dose
Formoterol fumarate Foradil Aerolizer Novartis Drug, Lactose Passive, Capsule,
Single dose
Foradil Certihaler Novartis Drug, Lactose monohydrate,
Magnesium stearate
Passive, Reservoir,
Multiple dose
Oxis Turbohaler AstraZeneca Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Easyhaler
Formoterol
Orion Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Indacaterol maleate Arcapta Neohaler Novartis Drug, Lactose monohydrate Passive, Capsule,
Single dose
Onbrez Breezhaler Novartis Drug, Lactose monohydrate Passive, Capsule,
Single dose
Tiotropium bromide Spiriva Handihaler Boehringer
Ingelheim
Drug, Lactose monohydrate Passive, Capsule,
Single dose
Aclidinium bromide Tudorza Pressair Forest Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Eklira Genuair AstraZeneca Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Glycopyrronium
bromide
Seebri Breezhaler Novartis Drug, Lactose monohydrate,
Magnesium stearate
Passive, Capsule,
Single dose
Umeclidinium Incruse Ellipta GlaxoSmithKline Drug, Lactose monohydrate,
Magnesium stearate
Passive, Blister strip,
Multi-unit dose
Budesonide Easyhaler
Budesonide
Orion Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Pulmicort
Flexhaler
AstraZeneca Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Pulmicort
Turbuhaler
AstraZeneca Drug Passive, Reservoir,
Multiple dose
Mometasone furoate Asmanex
Twisthaler
Merck Drug, Lactose Anhydrate Passive, Reservoir,
Multiple dose
Beclomethasone
dipropionate
Pulvinal
Beclometasone
Dipropionate
Chiesi Drug, Lactose monohydrate,
Magnesium stearate
Passive, Reservoir,
Multiple dose
Easyhaler
Beclometasone
Orion Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Fluticasone propionate Flovent Diskus GlaxoSmithKline Drug, Lactose monohydrate Passive, Blister strip,
Multi-unit dose
Fluticasone furoate Arnuity Ellipta GlaxoSmithKline Drug, Lactose monohydrate Passive, Blister strip,
Multi-unit dose
Beclomethasone
dipropionate + Formoterol
fumarate
Fostair Nexthaler Chiesi Drug, Lactose monohydrate,
Magnesium stearate
Passive, Reservoir,
Multiple dose
Budesonide + Formoterol
fumarate
Symbicort
Turbohaler
AstraZeneca Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
DuoResp
Spiromax
Teva Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Fluticasone
furoate + Vilanterol
Breo Ellipta GlaxoSmithKline Drug, Lactose monohydrate,
Magnesium stearate
Passive, Blister strip,
Multi-unit dose
Fluticasone
propionate + Salmeterol
Advair Diskus GlaxoSmithKline Drug, Lactose monohydrate Passive, Blister strip,
Multi-unit dose
Umeclidinium + Vilanterol Anoro Ellipta GlaxoSmithKline Drug, Lactose monohydrate,
Magnesium stearate
Passive, Blister strip,
Multi-unit dose
Glycopyrronium bromide +
Indacaterol maleate
Ultibro
Breezhaler
Novartis Drug, Lactose monohydrate,
Magnesium stearate
Passive, Capsule,
Single dose
Aclidinium
bromide + Formoterol
fumarate
Duaklir Genuair AstraZeneca Drug, Lactose monohydrate Passive, Reservoir,
Multiple dose
Cystic
fibrosis
infection
Tobramycin TOBI Podhaler Novartis Drug, 1, 2-distearoyl-sn-
glycero-3-phosphocholine,
Calcium chloride, Sulfuric
acid
Passive, Capsule,
Single dose
Influenza Zanamivir Relenza
Diskhaler
GlaxoSmithKline Drug, Lactose Passive, Blister strip,
Multi-unit dose
Diabetes Insulin human Afrezza Sanofi Aventis Drug, Fumaryl
diketopiperazine,
Polysorbate 80
Passive, Cartridge,
Single dose
Exubera (removed
from the market)
Pfizer Drug, Mannitol, Sodium
citrate, Glycine, Sodium
hydroxide
Active, Blister, Single
dose
Schizophrenia/
Bipolar disorder
Loxapine Adasuve Teva Drug Passive, Disposable
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Table 3 – The nebulizers in the US & UK markets.
Indications APIs Products Manufacter Formulation Device
Asthma and
COPD
Albuterol sulfate AccuNeb Mylan Drug, Sodium chloride,
Sulfuric acid (Solution)
Salbutamol Salbutamol
Inhalation
Solution
Focus Drug, Sodium chloride,
Dilute sulfuric acid, Sodium
hydroxide solution (Solution)
Formoterol
fumarate
Perforomist Mylan Drug, Sodium chloride,
Sodium citrate, Citric acid
(Solution)
Pari LC Plus nebulizer (with a
facemask or mouthpiece) and
Proneb Ultra compressor
Arformoterol
tartrate
Brovana Sunovion Drug, Sodium citrate, Citric
acid (Solution)
Pari LC Plus nebulizer (with
mouthpiece) and Pari Dura
Neb™3000 compressor
Olodaterol Striverdi
Respimat
Boehringer
Ingelheim
Drug, Benzalkonium
chloride, Edetate disodium,
Anhydrous citric acid
(Solution)
Spiriva Respimat inhaler
Tiotropium Spiriva
Respimat
Boehringer
Ingelheim
Drug, Edetate disodium,
Benzalkonium chloride,
Hydrochloric acid (Solution)
Spiriva Respimat inhaler
Budesonide Pulmicort
Respules
AstraZeneca Drug, Sodium chloride,
Sodium citrate, Citric acid,
Disodium edetate,
Polysorbate 80 (Suspension)
Pari-LC-Jet Plus Nebulizer/Pari
Master compressor system
Cromolyn sodium Intal
Nebulizer
Sanofi Aventis
Tiotropium + Olodaterol Stiolto
Respimat
Boehringer
Ingelheim
Drug,Water for injection,
Benzalkonium chloride,
Edetate disodium,
Hydrochloric acid (Solution)
Ipratropium
bromide + albuterol
Combivent
Respimat
Boehringer
Ingelheim
Drug, Benzalkonium
chloride, Edetate disodium,
Hydrochloric acid (Solution)
Combivent Respimat inhaler
Ipratropium
bromide + albuterol
sulfate
Duoneb Mylan Drug, Sodium chloride,
Hydrochloric acid, Edetate
disodium (Solution)
Pari LC Plus nebulizer (with
face mask or mouthpiece) and
Proneb,compressor
Bronchospasm Albuterol sulfate Ventolin
Solution
GlaxoSmithKline Drug, Benzalkonium
chloride, Sulfuric acid
(Solution)
Levalbuterol
hydrochloride
Xopenex Sunovion Drug, Sodium chloride,
Sulfuric acid (Solution)
Pari LC Jet and Pari LC Plus
nebulizers and PARI
Master Dura-Neb 2000 and
Dura-Neb 3000 compressors
Cystic fibrosis
infection
Tobramycin Bethkis Chiesi Drug, Sodium chloride,
Sulfuric acid (Solution)
Pari LC Plus Reusable Nebulizer
and Pari Vios Air compressor
Tobi Novartis Drug, Sodium chloride,
Sulfuric acid, Sodium
hydroxide (Solution)
Pari LC Plus Reusable Nebulizer
and DeVilbiss Pulmo-Aide
compressor
Kitabis Pak Pulmoflow Drug, Sodium chloride,
Sulfuric acid, Sodium
hydroxide (Solution)
Pari LC Plus Reusable Nebulizer
and DeVilbiss Pulmo-Aide air
compressor
Aztreonam Cayston Gilead Drug, Sodium chloride,
Lysine (Solution)
Altera Nebulizer System
Dornase alfa Pulmozyme Genentech Drug, Sodium chloride,
Dornase alfa, Calcium
chloride dihydrate (Solution)
eRapid Nebulizer System
(eRapid)
Infection Ribavirin Virazole Valeant I-neb AAD System
Pulmonary
arterial
hypertension
(PAH)
Iloprost Ventavis Actelion Drug, Ethanol, Sodium
chloride, Tromethamine,
Hydrochloric acid (Solution)
I-neb AAD (Adaptive Aerosol
Delivery) System
Treprostinil Tyvaso United Therap Drug, Sodium chloride,
Sodium citrate, Sodium
hydroxide, Hydrochloric acid
(Solution)
Tyvaso Inhalation System
Nicotine
withdrawal
symptoms
Nicotine Nicotrol Pfizer Drug, Menthol (Solution) Nicotrol Inhaler
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fill weight. The container headspace is filled by the vapor of
propellant; following actuations during the pMDI use, the
headspace of canister increases and more propellant evapo-
rates to fill the headspace, which causes the concentration of
drug in the liquid phase of the formulation and thus influ-
ences the delivered dose content uniformity through container
life [24].The actuator atomizes the formulation, thus its orifice
diameter influences the drug particle size distribution. The
orifice diameter usually ranges from 0.14 mm to 0.6 mm [25].
The fine particle dose and fine particle fraction can be in-
creased by utilizing smaller orifice diameter actuators [26].The
effect of the actuator orifice size on the amount of fine par-
ticles is more pronounced for solution pMDIs than for
suspension ones, as the particle size of the drug substance is
the limiting factor of the final particle size of pMDIs.
2.3. Patient use
Since the first pMDI was introduced to themarket, pMDIs have
been evolving throughout the years to bemore effective, giving
it an important role in inhalation therapy because of the low
price, lowmaintenance and convenience of use. From the point
of patient use, pMDIs actively deliver drug aerosols. All pMDIs
have the same drug delivery mechanism. They use high-
pressure liquefied propellants to atomize the formulation into
small droplets capable of delivering drug into the deep regions
of the respiratory tract [7]. Thus all pMDIs show similar size
and shape,and require similar inhalation techniquewhen being
used. The major drawback for pMDIs is the requirement for
coordinationbetweenactuation andpatient inhalation,andpoor
coordination may result in high drug deposition in the throat
region [27].This can be overcomebyusing breath-actuated pMDI
device such as Qvar Autohaler, a spacer or a valved holding
chamber. Spacers and valved holding chambers increase the
delay time between actuation and inhalation, allowing more
time for propellant evaporation, and decelerate the particles,
and thus they not only help the coordination, but they also in-
crease the pulmonary deposition [28,29]. In 2003, the FDA
recommended (but did not mandate) the addition of dose
counter or dose indicator on pMDIs to help patients ascertain
the remaining dose during use [30].The dose counter has been
observed in many market products, as shown in Table 1.
Clinically, all the current marketed pMDIs are for broncho-
spasm in asthma and COPD. The pMDI of albuterol, a short
acting β2-agonist (SABA), is still the most widely used medi-
cine for the treatment or prevention of bronchospasm.The pMDI
of levabuterol (Xopenex), the R-enantiomer of albuterol, was
also launched. It was reported that levabuterol can stereo-
selectively bind with the β2-agonist receptor, which may
enhance the efficacy and reduce the toxicity [31]. As recom-
mended by the Global Initiative for Asthma guidelines, the ideal
maintenance treatment for asthma is a combination of long
acting β2-agonists (LABA) and inhaled corticosteroids (ICS).
Salmeterol and formoterol are representatives of the LABA
family that can reside for an extented period of time at the
receptor due to their hydrophobic property, thus providing a
long duration of action [32]. Among the five available pMDIs
of LABA/ICS combination in the market (Table 1), four products
consist of formoterol, possibly due to the fact that formoterol
not only has a long acting duration (>12 h), but also a fast onset
of action (<3 min) [32]. The pMDI available for COPD therapy
is Atrovent, which contains ipratropium bromide, a short-
acting muscarinic antagonist (SAMA). A combination pMDI
containing ipratropium bromide and albuterol (Combivent CFC)
is no longer available following the phaseout of CFC pMDIs.
3. DPIs
3.1. Formulation
The formulation compositions of DPI can be simple, mostly a
blend of micronized drug powder with larger carrier particles
(usually lactose monohydrate), or even pure micronized drug
powder (such as Pulmicort Turbuhaler). The production of DPI
formulation, however, has many particle engineering chal-
lenges from drug crystallization andmicronization,mixing and
blending of micronized drug(s) with carrier excipients, filling of
dry powder formulation into capsule/blister/inhaler, storage sta-
bility (e.g., aggregation, moisture uptake, etc.), to emptying of
powder from the inhaler when being used. Such a formula-
tion process is well reviewed byTelko and Hickey [33]. Most DPI
products in the market (Table 2) use a blend of micronized drug
(usually <5 μm) and coarse lactose particles (30–80 μm or larger)
as carriers. It is important to first characterize the shape and
surface morphology of drug substance, because its crystal habit
influences its particle aerodynamic behavior, thus further af-
fecting the lung deposition [33]. For example, elongated and
pollen-shaped particles have been found to exhibit higher lung
deposition efficiency [34,35]. Milling is currently still the mostly
widely used method to micronize drug substance. Amorphous
drug or excipient could be produced during the milling process,
which may lead to reduced flowability and dispersibility of the
DPI formulation. Furthermore, once re-crystallization occurs in
the formulation, capillary force and solid bridge may be formed
due to the release of excess water, thereby impacting the physi-
cal stability of mixture [36].These amorphous materials can be
induced into crystals by conditioning them in a humidity con-
trolled or organic solvent vapor environment [37,38]. Another
strategy to improve drug dispersibility is to modify the par-
ticle surface morphology by producing wrinkled or hollow-
porous particles. It has been shown that enhanced aerosol
performance of corrugated bovine serum albumin (BSA) powder
than smooth spherical BSA powder, which could be explained
by the lower contact area caused by the asperities of corru-
gated particles [39]. The hollow-porous particle as a novel
formulation technique has been intensively investigated. Due
to characteristics such as lower density and larger size, active
ingredients are readily dispersed by means of being contained
[40]. The lactose is used as carrier to reduce drug particle
aggregation and to improve the formulation flowability. In order
to achieve the desired respiratory size (generally <5 μm), the
micronized drugs are cohesive and normally form agglomer-
ates due to their small size and high relative surface area [41].
By adding larger lactose particles, the ordered mixture could
be formed, in which the fine drug particles will adhere to the
surface of lactose particles, thereby leading to good content
uniformity and flowability [42]. Fine lactose particles can also
be added to promote drug release from the coarse lactose par-
ticles, thus enhancing drug dispersibility and fine particle
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fraction [43]. Due to the above reasons, occupation of active sites
and co-agglomeration with drug particles as two major mecha-
nisms have been concluded by Jones and Price [44]. Drug
dispersibility can also be affected by the morphology of coarse
lactose particles, such as the surface roughness and particle
shape [45,46]. Some recently developed DPI products, such as
Anoro Ellipta and Ultibro Breezhaler, have magnesium stea-
rate except for lactose in the formulations. It was reported that
magnesium stearate is hydrophobic,which can providemoisture
resistance, thus improving the formulation storage stability [47].
The mechanofusion with magnesium stearate also seems to in-
crease the fine particle fraction (FPF) of DPIs, thereby delivering
the drugs more effectively. The increased FPF might be attrib-
uted to the appropriate increase of surface energy and the
homogenizing of the surface adhesiveness [48]. Mannitol is an
alternative to lactose for drugs such as peptides or proteins (e.g.,
in Exubera insulin DPI), as these drugs may interact
with the reducing sugar function of the lactose through
Maillard reaction [49].The formulation–excipients blend homo-
geneity is not only affected by the physicochemical properties
of drugs and excipients, but also by the production factors such
as mixer selection and mixing process control [50–52].
PulmicortTurbuhaler contains a soft spherical pellet formula-
tion of pure drugs without any excipients,which avoids the blend
problems [53]. Other drug powder production techniques also
include spray drying, freeze drying, solvent precipitation and
others [54,55]; for examples, the PulmoSphere andTechnoSphere
technologies have been commercialized with the regulatory ap-
proval ofTOBI Podhaler andAfrezza, respectively.The engineered
particles obtained from these technologies not only contrib-
ute to the improvement in drug dose consistency and lung
target, but also facilitate the transport of active drug across
the biological membranes, resulting in a rapid onset of action
[56–58].These technologies can be used for drugs with large
doses.
3.2. Device
There are about 30 marketed DPIs and dozens of new devices
that are being reported [5]. All available DPI devices in the US
and UK markets are passive inhalers, which rely on patient’s
breath to activate the drug delivery; therefore it is important
that the DPI device is independent of the patient’s inspira-
tory effect [59]. DPI devices can be sorted into single dose
inhaler, reservoir based multi-dose inhaler, blister or car-
tridge based multi-dose inhaler, and single use (disposable)
inhaler. For single dose inhaler, the pre-metered formulation
is packaged in a hardcapsule (e.g. Spiriva Handihaler), a blister
(e.g. Exubera), or a cartridge (e.g. Afrezza). Most marketed DPIs
are reservoir based devices (Table 2) in which sufficient for-
mulation is stored in a chamber reservoir and a fixed amount
of powder is metered into a dosing receptacle for each dose.
The most reknown DPI device is the Advair Diskus, which is
a multi-unit device containing a foil blister strip filled with pre-
metered formulation. Its next generation device, Ellipta, is the
first DPI that enables simultaneous delivery of two drugs
without the need for co-formulation. The recently approved
Adasuve DPI utilizes a single use device. Such disposable device
can be a good option for drugs which only require a single or
several doses to complete its course such as vaccine.The details
of new types of DPI device have recently been reviewed by Chan
et al. [1]. For all these types of DPIs, the usability of the device
is important in order to improve the patient compliance with
the treatment instruction and adherence to the therapy [60].
The factors of the device usability include, but not are limited
to, robustness, ease of use, low occurrence of errors, and er-
gonomics. In contrast to MDIs, each DPI has its own design with
a different drug delivery mechanism, thus requiring a differ-
ent inhalation instruction.Therefore, it is fair to consider “each
DPI as one dosage form”,mainly based on the different designs
of devices. These features could be reflected on the disper-
sion mechanisms, air flow resistance and flow rate dependence
of dry powder delivery devices.
3.3. Patient use
In contrast to pMDIs, DPIs deliver the drugs by utilizing the pa-
tient’s inspiration, thus avoiding the hand and breath
coordination for patient use. Such an advantage, however, may
also become an issue if the activation of a DPI is flow rate de-
pendent. Take Turbuhaler for example; it has been confirmed
that the increase of the air flow through budesonide/
formoterolTurbuhaler from 30 to 60 l/min led to approximately
double the total emitted dose and fine particle mass of both
drugs [61]. For the treatment and prevention of broncho-
spasm in asthma and COPD, the current DPI products have
covered the drug categories of SABA (short-acting β2 agonist),
LABA (long-acting β2 agonist), SAMA (short-acting muscarinic
antagonist), LAMA (long-acting muscarinic antagonist), and ICS
(inhaled corticosteroid). Multiple combination DPIs of ICS/
LABA are available and new device based combination DPIs are
continuously being launched.The recently approved Breo Ellipta
is the first member of the ICS/LABA class to shift from twice-
daily to once-daily treatment [62,63]. Another category of
combination DPIs that consists of LAMA/LABA are formu-
lated for COPD treatment. The utilization of DPIs is being
expanded to drugs for new indications, including antibiotics,
antivirus, insulin, and vaccines. The DPI of tobramycin (TOBI
Podhaler) is introduced to reduce treatment time and improve
ease of use compared with tobramycin inhalation solution in
cystic fibrosis (CF) patients. It is comparable to inhalation so-
lution in efficacy outcomes and safety profile but has greater
patient satisfaction in all the age groups [64]. Although Pfizer’s
inhaled insulin DPI (Exubera) was withdrawn due to poor re-
ception in the market, its successful launch in 2006 started a
new era for inhalation therapy as a route for systemic drug ad-
ministration. The launch of the second insulin DPI, Afrezza,
is an indication of continuous efforts from pharmaceutical in-
dustries to apply the DPI technology to systemic drugs.
4. Nebulizers
4.1. Formulation
Nebulizers are the oldest device for respiratory drug delivery.
The drug is formulated in aqueous solution or suspension,which
is atomized into fine droplets via an external nebulization source
while being used for inhalation. These aqueous-based oral
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inhalation solutions and suspensionmust be sterile, and are typi-
cally packaged in single-use containers (usually 1–3 ml) [65].
Sterile water for injection is normally used as solvent, and in
some cases, ethanol can also be used as the co-solvent. Sodium
chloride is usually used to adjust the isotonicity. In most cases,
pH values are adjusted by acid or base, such as hydrochloric acid
or sodium hydroxide. For easily oxidized drugs, edetate diso-
dium is added in formulation as a chelating agent to further
remove the tracedmetal ions, and nitrogen is used for sparging,
filling and pouching. Surfactants such as polysorbate 80 can be
used to enhance the suspension stability (such as Pulmicort
Respiles).Antimicrobial preservatives such as benzalkonium chlo-
ride are added if needed. Inhalation of nebulized solution/
suspension requires performance tests of drug delivery rate
(output) and aerodynamic droplet size distribution, which are
the product’s critical quality attributes (CQAs). It is important
to study well and understand how the key formulation param-
eters, such as viscosity, surface tension and drug concentration,
influence these CQAs [1,66]. It was reported that an increase of
solution viscosity could slow down the nebulization and reduce
the drug output for jet nebulizers, and the primary droplet size
was proportional to the surface tension [67]. For the vibrating
mesh nebulizers, increasing solution viscosity decreased droplet
size, but prolonged nebulization time.The electrostatic charges
present in the aqueous solutions inhibited the flow and de-
tachment of fluid through the mesh, and the introduction of
electrolytes could suppress the charges, thus improving par-
ticle size, drug output and nebulization time [68]. The drug
concentration influenced the nebulizer output and such an effect
was related to the type of nebulizers.When antibiotic concen-
tration was increased, the output decreased more precipitously
with the ultrasonic nebulizers than with the jet nebulizers.The
drug concentration had less effect on the droplet size distribu-
tion [69].
4.2. Device
Jet nebulizer, powered by compressed air, is still the most uti-
lized apparatus for inhalation solution/suspension. But the jet
nebulizer is cumbersome and somewhat noisy to use, and has
a long dosing duration (10–15 minutes).The cooling effect of jet
nebulizers due to the expansion of atomizing gas and evapo-
ration of solvent also influences patient’s use. Ultrasonic
nebulizer generates aerosol by electronically induced vibra-
tion of a ceramic piezoelectric element. It is compact and silent,
and the dosing time is shorter than that of the jet nebulizers,
as the emit of ultrasonic nebulizers is higher than that of jet
nebulizers [70]. Heat, however, is generated during the ultra-
sonic nebulization process, thus it is unsuitable for heat sensitive
drugs [71]. Vibrating mesh nebulizers are a recent technology
that uses vibrating perforated mesh to generate respirable sized
droplets.They are electronic devices and have advantages over
both jet and ultrasonic nebulizers, such as fast treatment time,
minimal residual dose, and reduced drug waste. Clog of the tiny
holes of the mesh and high cost are the drawbacks [72]. A por-
table nebulizer device, Spiriva Respimat, has been launched by
Boehringer Ingelheim. The nebulized solution is filled into a
plastic container crimped into an aluminum cylinder (car-
tridge) for use with the Respimat inhaler.The Respimat inhaler
is a handheld, pocket sized oral inhalation device that uses a
compressed spring producing mechanical energy to generate a
slow-moving aerosol cloud ofmedication from ametered volume
of the drug solution. Due to its difference in terms of atomiza-
tion mechanisms and device designs, the device is yet to be
classified as nebulizer while someone prefers to consider it as
propellant free MDI or metered dose liquid inhaler (MDLI) [73].
Such a portable device contains multiple doses and is able to
deliver the drug in a single breath of soft mist without the need
for continuous inhalations, and thus should be the future di-
rection for new nebulizer development.
4.3. Patient use
Currently nebulizers remain widely utilized in hospitals and
home settings.They allow the patients to inhale the drug aero-
solswith tidal breathingmaneuvers and little training required.
Therefore, it can be used for patients who are unable to co-
ordinate their breathing or activate the inhalers such as MDI
or DPI, especially for the elderly and children. Most inhalation
solutions/suspensions for asthmaandCOPDconsist of oneactive
drug of SABA, LABA or LAMA.Most recently, the FDA approved
the inhalation sprayof LAMA/LABA (Tiotropium/Olodaterol) com-
bination, which can be given to patients once daily.
Nebulizers can continuously deliver drugs for a long dosing
duration, thus are suitable for large dose drugs, such as anti-
biotics. Tobramycin was the first antibiotics approved as an
inhalation solution (TOBI) for the prevention and treatment of
Pseudomonas aeruginosa infection in cystic fibrosis. A long-
term therapy study indicated that inhaled tobramycin improved
lung function and reduced exacerbation rate for patients with
CF [74].The other clinical applications of nebulizers include pul-
monary arterial hypertension and nicotinewithdrawal symptoms
(Table 3).
Nebulizers are not typically used for chronic-disease man-
agement because they are larger and less convenient than
pMDIs and DPIs. It is critical that the inhalation solution/
suspension should be delivered using the specific nebulizer
recommended in drug package insert in order to obtain the
expected emitted dose, particle size distribution and formu-
lation emptying time while being used [75]. Different droplet
size distribution was observed with the same nebulizer while
different compressors or different compressor pressures were
utilized [69].With traditional jet nebulizers, only 10% of the dose
may reach the lung.The majority of the drug is either remain-
ing in the nebulizer or released into the surrounding air during
expiration [67]. Breath enhanced device (e.g. Pari LC Star) or
breath actuated device (e.g. AeroEclipse II) have been devel-
oped to create aerosols only during inspiration, thus reducing
drug wastage and improvimg delivery efficiency [66,76].
5. Regulations on development of inhalation
drug products
The FDA and EMA have published guidelines on the develop-
ment of all these three types of inhalation drug products (pMDI,
DPI and inhalation solution/suspension for nebulizer) [7,65,77].
Following the patent expiration for many inhalation prod-
ucts, especially the blockbuster drugs such as Advair Diskus,
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the switch from branded to generic inhalation medicine is a
worldwide trend, and the development of generic inhalers has
been a hot area for pharmaceutical industries.
The EMA in 2009 issued the guideline on the demonstra-
tion of therapeutic equivalence between two inhaled products,
which described a step-wise approach for the approval of
generic inhalation drug products [78]. From the point of for-
mulation, the generic and the reference products should be the
identical dosage form with the same active substance(s). Any
differences in crystalline structure and/or polymorphic form
of the active substance and any qualitative and/or quantita-
tive differences in excipients should not influence the
pharmaceutical performance and safety profile of the product.
Regarding the device, the handling and resistance to airflow
of the generic and reference products should be the same.The
critical quality attributes to assess the in vitro equivalence
between the generic and reference products are the dose de-
livery uniformity and particle size distribution profile. The
delivered dose should be similar (within 15%). The compari-
son of particle size distribution, tested by a validated multistage
impactor, should be performed per impactor stage or justi-
fied group of stages with suitable equivalence criteria (e.g. 15%
may be justifiable). If a generic product satisfies all of the above
pharmaceutical criteria for equivalence, the use of only in vitro
data may be considered acceptable for product approval. Oth-
erwise, in vivo studies (pharmacokinetics or pharmacodynamics)
should be performed to substantiate equivalence.
Rather than issuing a general guideline as the EMA did, the
FDA has published five separate draft guidance for each spe-
cific inhalation product: pMDIs of albuterol sulfate, ipratropium
bromide, levalbuterol tartrate, budesonide/formoterol fuma-
rate, and DPI of fluticasone propionate/salmeterol [79–83],
starting from 2013. Based on the FDA guidance, it will be a very
difficult process to get FDA approval in the US for generic
product as it requires that the in vitro tests, pharmacokinet-
ics and pharmacodynamics all substantiate equivalence [84].
The in vitro tests include single actuation content (SAC) and
aerodynamic particle size distribution (APSD). Equivalence in
spray pattern, plume geometry, priming and repriming studies
are also required for generic pMDIs, apparently for support-
ing the similarity of valves and actuators. The similarity
requirements of DPI device include the device mechanism, pre-
metered multi-dose format, doses, operating procedures, size,
shape, device resistance and dose counter. For the formula-
tion, the generic product should use the same inactive
ingredient(s) as the reference product (i.e. qualitative same-
ness; Q1), and the concentration of the inactive ingredient(s)
used in the generic product should be within 5% of those used
in the reference product (i.e. quantitative sameness; Q2). The
draft guidance has been challenged by industries. Rather than
the Q2 requirement, it is proposed to utilize the quality-by-
design (QbD) approach to study the control space of the
excipient concentration for the generic product [85].
6. Conclusions
pMDI, DPI and nebulizer each has its specific advantages and
limits.The increasing interest in the pulmonary route for both
local and systemic acting drugs continues to promote the de-
velopment of new inhalation drug products for new indications,
together with new formulation and device technologies. The
development of inhalation drugs should practically consider
factors such as patient preference, convenience of use, and cost,
as the final target goal is to improve patient adherence and
therapeutic outcomes.
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